TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation

Current Topics in Medicinal Chemistry

Volumn 11, Issue 17, 2011, Pages 2151-2158

  Blumberg, Peter M ^a   Pearce, Larry V ^a   Lee, Jeewoo ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Seoul National University   (South Korea)

Author keywords

Capsaicin; Efficacy; Partial agonist; Partial antagonist; Resiniferatoxin; Signaling pathway; TRPV1

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (5 ISOQUINOLINYL) 3 [4 (TRIFLUOROMETHYL)BENZYL]UREA; 5 IODORESINIFERATOXIN; AMG 7905; AMG 8562; CAPSAICIN; JYL 1421; JYL 1511; JYL 1522; JYL 827; KJM 429; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; RESINIFERATOXIN; SC 0030; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ARTICLE; ASTHMA; COMPETITIVE INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; KINETICS; LIPOPHILICITY; NONHUMAN; PAIN; PARTIAL AGONISM; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; URGE INCONTINENCE;

ANIMALS; CAPSAICIN; CHEMISTRY, PHARMACEUTICAL; DITERPENES; DRUG DESIGN; DRUG PARTIAL AGONISM; HUMANS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS;

EID: 80052207553     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796904825     Document Type: Article

References (73)

1. Buck, S.H.; Burks, T.F. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol. Rev., 1986, 38, 179-226.
2. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience, 1988, 24, 739-768.
3. Szallasi, A.; Blumberg, P.M. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain, 1996, 68(2-3), 195-208.
4. Walpole, C.S.J.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Perkins, M.N.; Reid, D.J.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region". J. Med. Chem., 1993, 36, 2362-2372.
5. Walpole, C.S.J.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Masdin, K.J.; Perkins, M.N.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". J. Med. Chem., 1993, 36, 2373-2380.
6. Walpole, C.S.J.; Wrigglesworth, R.; Bevan, S.; Campbell, E.A.; Dray, A.; James, I.F.; Masdin, K.J.; Perkins, M.N.; Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region". J. Med. Chem., 1993, 36, 2381-2389.
7. Janusz, J.M.; Buckwalter, B.L.; Young, P.A.; LaHann, T.R.; Farmer, R.W.; Kasting, G.B.; Loomans, M.E.; Kerckaert, G.A.; Maddin, C.S.; Berman, E.F.; Bohne, R.L., Cupps, T.L.; Milstein, J.R. Vanilloids. 1. Analogs of capsaicin with antinociceptive and anti-inflammatory activity. J. Med. Chem., 1993, 36, 2595-2604.
8. Appendino, G.; Szallasi, A. Euphorbium, modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci., 1997, 60(10), 681-696.
9. Szallasi, A.; Blumberg, P.M. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience, 1989, 30, 515-520.
10. Szallasi, A.; Blumberg, P.M. Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root ganglion membranes. Brain Res., 1990, 524(1), 106-111.
11. Szallasi, A.; Blumberg, P.M. Characterization of vanilloid receptors in the dorsal horn of pig spinal cord. Brain Res., 1991, 547(2), 335-338.
12. Szolcsanyi, J.; Jancso-Gabor, A. Sensory effects of capsaicin congeners. I. Relationship between chemical structure and pain-producing potency of pungent agents. Arzneim.-Forsch., 1975, 25(12), 1877-1881.
13. Tominaga, M.; Caterina, M.J.; Malmberg, A.B.; Rosen, T.A.; Gilbert, H.; Skinner, K.; Raumann, B.E.; Basbaum, A.I.; Julius, D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron, 1998, 21(3), 531-543.
14. Bley, K.R. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin. Investig. Drugs, 2004, 13(11), 1445-1456.
15. Broad, L.M.; Keding, S.J.; Blanco, M.J. Recent progress in the development of selective TRPV1 antagonists for pain. Curr. Top. Med. Chem., 2008, 8(16), 1431-1441.
16. Gunthorpe, M.J.; Chizh, B.A. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov. Today, 2009, 14(1-2), 56-67.
17. Lazar, J.; Gharat, L., Khairathkar-Joshi, N., Blumberg, P.M.; Szal-lasi, A. Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade. Expert Opin. Drug Discov., 2009, 4(2), 159-180.
18. Pal, M.; Angaru, S.; Kodimuthali, A.; Dhingra, N. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management. Curr. Pharm. Des., 2009, 15(9), 1008-1026.
19. Dickenson, A.H.; Dray, A. Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception. Br. J. Pharmacol., 1991, 104(4), 1045-1049.
20. Urban, L.; Dray, A. Capsazepine, a novel capsaicin antagonist, selectively antagonizes the effects of capsaicin in the mouse spinal cord in vitro. Neurosci. Lett., 1991, 134(1), 9-11.
21. Wahl, P.; Foged, C.; Tullin, S.; Thomsen, C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol. Pharmacol., 2001, 59, 9-15.
22. Wang, Y.; Szabo, T.; Welter, J.D.; Toth, A.; Tran, R.; Lee, J.; Kang, S.U.; Suh, Y.G.; Blumberg, P.M.; Lee, J. High affinity antagonists of the vanilloid receptor. Mol. Pharmacol., 2002, 62(4), 947-956.
23. Gavva, N.R.; Tamir, R.; Klionsky, L.; Norman, M.H.; Louis, J.C.; Wild, K.D.; Treanor, J.J. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol. Pharmacol., 2005, 68(6), 1524-1533.
24. McIntyre, P.; McLatchie, L.M.; Chambers, A.; Phillips, E.; Clarke, M.; Savidge, J.; Toms, C.; Peacock, M.; Shah, K.; Winter, J.; Weerasakera, N.; Webb, M.; Rang, H.P.; Bevan, S.; James, I.F. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br. J. Pharmacol., 2001, 132, 1084-1094.
25. Savidge, J.; Davis, C.; Shah, K.; Colley, S.; Phillips, E.; Ra-nasinghe, S.; Winter, J.; Kotsonis, P.; Rang, H.; McIntyre, P. Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacology, 2002, 43, 450-456.
26. Wang, Y.; Toth, A.; Tran R.; Szabo, T.; Welter, J.D.; Blumberg, P.M.; Lee, J.; Kang, S.U.; Lim, J.O.; Lee, J. High-affinity partial agonists of the vanilloid receptor. Mol. Pharmacol., 2003, 64(2), 325-333.
27. Matthews, P.J.; Aziz, Q.; Facer, P.; Davis, J.B.; Thompson, D.G.; Anand, P. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur. J. Hepatol., 2004, 16, 897-902.
28. Tympanidis, P.; Casula, M.A.; Yiangou, Y.; Terenghi, G.; Dowd, P.; Anand, P. Increased vanilloid receptor VR1 innervation in vul-vodynia. Eur. J. Pain, 2004, 8, 129-133.
29. Groneberg, D.A.; Niimi, A.; Dinh, Q.T.; Cosia, B.; Hew, M.; Fischer, A.; Chung, K.F. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am. J. Crit.Care Med., 2004, 170, 1276-1280.
30. Mukerji, G.; Yiangou, Y.; Agarwal, S.K.; Anand, P. Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. J. Urol., 2006, 176, 797-801.
31. Ji, R.R.; Samad, T.A.; Jin, S.X.; Schmoll, R.; Woolf, C.J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperpla-sia. Neuron, 2002, 36, 57-68.
32. Zhang, N.; Inan, S.; Cowan, A.; Sun, R.; Wang, J.M.; Rogers, T.J.; Caterina, M.; Oppenheim, J.J. A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc. Natl. Acad. Sci. USA, 2005, 102(12), 4536-4541.
33. Cortright, D.N.; Szallasi, A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur. J. Biochem., 2004, 271(10), 1814-1819.
34. Pearce, L.V.; Toth, A.; Ryu, H.; Kang, D.W.; Choi, H.K.; Jin, M.K.; Lee, J.; Blumberg, P.M. Differential modulation of agonist and antagonist structure activity relations for rat TRPV1 by cy-closporin A and other protein phosphatase inhibitors. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(2), 149-157.
35. Roberts, L.A.; Christie, M.J.; Connor, M. Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse tri-geminal sensory neurons. Br. J. Pharmacol., 2002, 137, 421-428.
36. Smart, D.; Gunthorpe, M.J.; Jerman, J.C.; Nasir, S.; Gray J.; Muir, A.I.; Chambers, J.K.; Randall, A.D.; Davis, J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Brit. J. Pharmacol., 2000, 129, 227-230.
37. Shimizu, I.; Iida, T.; Horiuchi, N.; Caterina, M.J. 5-iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J. Pharmacol. Exp. Ther., 2005, 314, 1378-1385.
38. Appendino, G.; Minassi, A.; Morello, A.S.; DePetrocellis, L.; Di Marzo, V. N-acylvanillamides; development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. J. Med. Chem., 2002, 45, 3739-3745.
39. McDonnell, M.E.; Zhang, S.P.; Dubin, A.E.; Dax, S.L. Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor. Bioorg. Med. Chem. Lett., 2002, 12, 1189-1192.
40. Appendino, G.; Harrison, S.; De Petrocellis, L.; Daddaria, N.; Bian-chi, F.; Moriello, A.S.; Trevisani, M.; Benvenuti, F.; Geppetti, P.; Di Marzo, V. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br. J. Pharmacol., 2003, 139(8), 1417-1424.
41. Appendino, G.; Daddario, N.; Minassi, A.; Moriello, A.S.; de Petrocellis, L.; di Marzo, V. The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J. Med. Chem., 2005, 48, 4663-4669.
42. Kang, D.W.; Ryu, H.C.; Lee, J.; Lang, K.A.; Pavlyukovets, V.A.; Pearce, L.V.; Ikeda, T.; Lazar, J.; Blumberg, P.M. Halogenation of 4-hydroxy-3-methoxybenzyl thiourea TRPV1. Agonists showed enhanced antagonism to capsaicin. Bioorg. Med. Chem. Lett., 2007, 17, 214-219.
43. Szallasi, A.; Blumberg, P.M.; Annicelli, L.L.; Krause, J.E.; Cor-tright, D.N.; The cloned rat vanilloid receptor VR1 mediates both R-type binding and C-type calcium response in dorsal root ganglion neurons. Mol. Pharmacol., 1999, 56(3), 581-587.
44. Toth, A.; Wang, Y.; Kedei, N.; Tran, R.; Pearce, L.V.; Kang, S.U.; Jin, M.K.; Choi, H.K.; Lee, J.; Blumberg, P.M. Different vanilloid agonists cause different patterns of calcium response in CHO cells heterologously expressing rat TRPV1. Life Sci., 2005, 76(25), 2921-2932.
45. Blumberg, P.M.; Kedei, N.; Lewin, N.E.; Yang, D.; Czifra, G.; Pu, Y.; Peach, M.L.; and Marquez, V.E. Wealth of opportunity - the C1 domain as a target for drug development. Curr. Drug Targets, 2008, 9, 641-652.
46. Wang, Q.J.; Fang, T.W.; Fenick, D.; Garfield, S.; Bienfait, B.; Marquez, V.E.; Blumberg, P.M. The lipophilicity of phorbol esters as a critical factor in determining the pattern of translocation of protein kinase C delta fused to green fluorescent protein. J. Biol. Chem., 2000, 275(16), 12136-12146.
47. Braun, D.C.; Cao, Y.; Wang, S.; Garfield, S.H.; Hur, G.M.; Blum-berg, P.M. Role of phorbol ester localization in determining protein kinase C or RasGRP3 translocation: real-time analysis using fluorescent ligands and proteins. Mol. Cancer Ther., 2005, 4(1), 141-150.
48. Lazar, J.; Braun, D.C.; Toth, A.; Wang, Y.; Pearce, L.V.; Pavlyuk-ovets, V.A.; Blumberg, P.M.; Garfield, S.H., Wincovitch, S.; Choi, H.K.; Lee, J. Kinetics of penetration influence the apparent potency of vanilloids on TRPV1. Mol. Pharmacol., 2006, 69(4), 1166-1173.
49. Toth, A.; Blumberg, P.M.; Chen, Z.; Kozikowski, A.P. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. Mol. Pharmacol., 2004, 65(2), 282-291.
50. McNamara, F.N.; Randall, A.; Gunthorpe, M.J. Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1). Brit. J. Pharmacol., 2005, 144, 781-790.
51. Xu, H.; Blair, N.T.; Clapham, D.E. Camphor activates and strongly desensitizes the transient receptor potential subtype 1 channel in a vanilloid-independent mechanism. J. Neurosci., 2005, 25, 8924-8937.
52. Szallasi, A.; Acs, G.; Cravotto, G.; Blumberg, P.M.; Lundberg, J.M.; Appendino, G. A novel agonist, phorbol 12-phenylacetate 20-homovanillate, abolishes positive cooperativity of binding by the vanilloid receptor. Eur. J. Pharmacol., 1996, 299(1-3), 221-228.
53. Appendino, G.; Cravotto, G.; Palmisano, G.; Annunziata, R.; Szal-lasi, A. Synthesis and evaluation of phorboid 20-homovanillates: discovery of a class of ligands binding to the vanilloid (capsaicin) receptor with different degrees of cooperativity. J. Med. Chem., 1996, 39, 3123-3131.
54. Caterina, M.J.; Leffler, A.; Malmberg, A.B.; Martin, W.J.; Trafton, J.; Petersen-Zeitz, K.R.; Koltzenburg, M.; Basbaum, A.I.; Julius, D. Imparied nociception and pain sensation in mice lacking the cap-saicin receptor. Science, 2000, 288(5464), 306-313.
55. Davis, J.B.; Gray, J.; Gunthorpe, M.J.; Hatcher, J.P.; Davey, P.T.; Overend, P.; Harries, M.H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S.A.; Rance, K.; Grau, E.; Harper, A.J.; Pugh, P.L.; Rogers, D.C.; Bingham, S.; Randall, A.; Sheardown, S.A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature, 2000, 405, 183-187.
56. Szelenyi, Z.; Hummel, Z.; Szolcsanyi, J.; Davis, J.B. Daily body temperature rhythm and heat tolerance in TRPV1 knockout and capsaicin pretreated mice. Eur. J. Neurosci., 2004, 19(5), 1421-1424.
57. Birder, L.A.; Nakamura, Y.; Kiss, S.; Nealen, M.L.; Barrick, S.; Kanai, A.J.; Wang, E.; Ruiz, G.; De Groat, W.C.; Apodaca, G.; Watkins, S.; Caterina, M.J. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat. Neurosci., 2002, 5(9), 856-860.
58. Zhong, B.; Wang, D.H. Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 297(6), R1681-1690.
59. Wang, Y.; Wang, D. H. Aggravated renal inflammatory responses in TRPV1 gene knockout mice subjected to DOCA-salt hypertension. Am. J. Physiol. Renal. Physiol., 2009, 297(6), F1550-1559.
60. Clark, N.; Keeble, J.; Fernandes, E.S.; Starr, A.; Liang, L.; Sugden, D.; de Winter, P.; Brain, S.D. The transient receptor potential vanil-loid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin. FASEB J., 2007, 21(13), 3747-3755.
61. Blednov, Y.A.; Harris, R.A. Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol. Neurophar-macol., 2009, 56(4), 814-820.
62. Bode, A.M.; Cho, Y.Y.; Zheng, D.; Shu, F.; Ericson, M.E.; Ma, W.Y.; Yao, K.; and Dong, Z. Transient receptor potential type va-nilloid 1 suppresses skin carcinogenesis. Cancer Res., 2009, 69(3), 905-913.
63. Swanson, D.M.; Dubin, A.E.; Shah, C.; Nasser, N.; Chang, L.; Dax, S.L.; Jetter, M.; Breitenbucher, J.G.; Liu, C.; Mazur, C.; Lord, B.; Gonzales, L.; Hoey, K.; Rizzolio, M.; Bogenstaetter, M.; Codd, E.E.; Lee, D.H.; Zhang, S.P.; Chaplan, S.R.; Carruthers, N.I. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem., 2005, 48, 1857-1872.
64. Gavva, N.R.; Bannon, A.W.; Surapaneni, S.; Hovland, D.N. Jr.; Lehto, S.G.; Gore, A.; Juan, T.; Deng, H.; Han, B.; Klionsky, L.; Kuang, R.; Le, A.; Tamir, R.; Wang, J.; Youngblood, B.; Zhu, D.; Norman, M.H.; Magal, E.; Treanor, J.J.; Louis, J.C. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci., 2007, 27(13), 3366-3374.
65. McGaraughty, S.; Segreti, J.A.; Fryer, R.M.; Brown, B.S.; Faltynek, C.R.; Kym, P.R. Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats. Brain Res., 2009, 1268, 58-67.
66. Steiner, A.A.; Turek, V.F.; Almeida, M.C.; Burmeister, J.J.; Oliveira, D.L.; Roberts, J.L.; Bannon, A.W.; Norman, M.H.; Louis, J.C.; Treanor, J.J.; Gavva, R.R.; Romanovsky, A.A. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci., 2007, 27(28), 7459-7468.
67. Tamayo, N.; Liao, L.; Stec, M.M.; Wang, X.; Chakrabarti, P.; Retz, D.; Doherty, E.M.; Surapaneni, S.; Tamir, R.; Bannon, A.W.; Gavva, N.R.; Norman, M.H. The design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. J. Med. Chem., 2008, 51, 2744-2757.
68. Gavva, N.R.; Bannon, A.W.; Hovland, D.N. Jr.; Lehto, S.G.; Klionsky, L.; Surapaneni, S.; Immke, D.C.; Henley, C.; Arid, L.; Bak, A.; Davis, J.; Ernst, N.; Hever, G.; Kuang, R.; Shi, L.; Tamir, R.; Wang, J.; Wang, W.; Zhu, D.; Norman, M.H.; Louis, J.C.; Ma-gal, E.; Treanor, J.J. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther., 2007b, 323(1), 128-137.
69. Gavva, N.R.; Treanor, J.J.S.; Garami, A.; Fang, L.; Surapaneni, S.; Akrami, A.; Alvarez, F.; Bak, A.; Darling, M.; Gore, A.; Jang, G.R.; Kesslak, J.P.; Ni, L.; Norman, M.H.; Palluconi, G.; Rose, M.J.; Salfi, M.; Tan, E.; Romanovsky, A.A.; Banfield, C.; Davar, G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain, 2008, 136, 202-210.
70. Lehto, S.G.; Tamir, R.; Deng, H.; Klionsky, L.; Kuang, R.; Le, A.; Lee, D.; Louis, J.C.; Magal, E.; Manning, B.H.; Rubino, J.; Sura-paneni, S.; Tamayo, N.; Wang, T.; Wang, J.; Wang, J.; Wang, W.; Youngblood, B.; Zhang, M.; Zhu, D.; Norman, M.H.; Gavva, N.R. Antihyperalgisic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanil-loid type 1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Therap., 2008, 326, 218-229.
71. Garami, A.; Shimansky, Y.P.; Pakai, E.; Oliveira, D.L.; Gavva, N.R.; Romanovsky, A.A. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J. Neurosci., 2010, 30(4), 1435-1440.
72. Mills, C.; McMackin, M.; Jaffe, R.; Yu, J.; Zininberg, E.; Slee, D.; Gogas, K.; Bradbury, M. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and ther-moregulation in the rat. Neurosci., 2008, 156, 165-174.
73. Honore, P.; Chandran, P.; Hernandez, G.; Gauvin, D.M.; Mikusa, J.P.; Zhong, C.; Joshi, S.K.; Ghilardi, J.R.; Sevcik, M.A.; Freyer, R.M.; Segreti, J.A.; Banfor, P.N.; Marsh, K.; Neelands, T.; Bay-burt, E.; Daanen, J.F.; Gomtsyan, A.; Lee, C.H.; Kort, M.E.; Reilly, R.M.; Surowy, C.S.; Kym, P.R.; Mantyh, P.W.; Sullivan, J.P.; Jarvis, M.F.; Faltynek, C.R. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyper-thermia. Pain, 2009, 143(1-2), 27-35.